FDA Approves High Blood Pressure Drug
Azilsartan medoxomil, also known as Edarbi, is a hypertension drug that has been shown to be more effective in lowering 24-hour blood pressure compared with two other FDA-approved hypertension drugs, Diovan (valsartan) and Benicar (olmesartan). It is made by Takeda Pharmaceutical North America.
Tablets are available in 80 milligram and 40 mg doses, with the recommended dose set at 80 mg once daily. The 40 mg dose will be available for patients who are treated with high-dose diuretics taken to reduce salt in the body.
Edarbi is an angiotensin II receptor blocker (ARB) that lowers blood pressure by blocking the action of angiotensin II, a vasopressor hormone.
Adverse reactions reported by patients in clinical trials were similar to those reported by those taking an inactive drug (placebo).
For more information: www.tpna.com